ClinicalTrials.gg
RecruitingNCT04844242COVID-19Updated May 30, 2024

MISC COVID-19 Study in Pediatric Population

An observational study in SARS-CoV2 Infection and Multisystem Inflammatory Syndrome in Children, sponsored by Tuberculosis Research Centre, India. Recruiting at 1 site in India. Open to participants aged 1 Year to 15 Years. Per ClinicalTrials.gov, last updated 2024-05-30.

Sponsored by Tuberculosis Research Centre, India · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Dec 2020; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
180
Ages
1 Year to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 113 studies in COVID-19 with a site in India — 7 open to participants now, 9 under way, 4 of them phase 3. COVID-19 · India.

Planned enrollment
29th of 38
180 · median 598
Started
2020
with 52 others
Observational
38 of 113
3 open now
Registered
62nd of 113
by date

Among the 113 studies in COVID-19 with a site in India, this one is the 29th largest by planned enrollment of the 38 observational ones that give a count, is one of 53 that started in 2020, is one of 38 observational ones, and was the 62nd registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

7 of the 113 studies in COVID-19 with a site in India are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 1 Year to 15 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies in COVID-19 with a site in India, or all of them as a file.
02

Study summary

Rationale: Severe Acute Respiratory Syndrome - Coronavirus - 2 (SARS-CoV2) and its related Coronavirus Disease - 19 (COVID-19) has become a health emergency worldwide. The medical community has been concerned since the beginning of the outbreak about the potential impact of COVID-19 in children, especially in those with underlying chronic diseases. Fortunately, COVID-19 has been reported to be less severe in children than in adults. Unfortunately, a new multisystem inflammatory syndrome apparently related to infection with SARS-CoV-2 has recently been reported in older children (known as MIS-C), manifested by severe abdominal pain, cardiac dysfunction and shock. However, the SARS-CoV2 infection and the underlying immunology of COVID-19, its correlation with disease severity and MIS-C in children is not fully explored.

Objectives: To perform systems immunology and strain diversity among SARS-CoV2 and MIS-C infected children.

Study design: Cross sectional study. Study population: Children attending outpatients units and admitted in wards in pediatric hospitals in Chennai.

Main study parameters/endpoints: Immune responses in children with SARS-CoV2 infection and multisystem inflammatory syndrome in children (MIS-C) infection and its association of SARS-CoV2 viral diversity.

Read the detailed description

Scientific Background:

COVID-19 is a global health crisis. The clinical characteristics, disease progression and outcome in children and young adults appear significantly milder compared to older individuals. Since first being reported in Wuhan, China in December 2019, COVID-19 has rapidly spread, affecting over 200 countries worldwide. Children account for 1-5% of diagnosed COVID-19 cases; although, many infected children may be asymptomatic and therefore not diagnosed without population screening. Most infected children are likely to be secondary cases and acquire the infection after exposure to a COVID-19 positive adult, although there are no longitudinal data to confirm this yet. Intra-family transmission may be important since, an unquantified proportion of children with COVID-19 areasymptomatic and may contribute to transmission. Multiple reports have demonstrated that children and young adults have a milder form of the disease compared to adults. Asymptomatic, mild and moderate infections comprise over 90% of all children who have tested positive for COVID-19 with fewer severe and critical cases (5.9%) compared to adults (18.5%). Given that severe COVID-19 appears very rare in children, an important part of this assessment is ascertaining whether a positive RT-PCR for SARS-CoV-2 is a clinically important factor in explaining the child's condition, or whether more occult pathology may be responsible.

When the COVID-19 pandemic was first reported in Asia and initially spread throughout the globe, pediatricians were grateful that children seemed to be only mildly symptomatic with the infection in most cases. Then, an alarming warning came from the National Health Service in England in April 2020 about cases of older school-aged children and adolescents presenting with fever, hypotension, severe abdominal pain and cardiac dysfunction who tested positive for SARS-CoV-2 infection either by nasopharyngeal RT-PCR assay or by antibody testing. These children had laboratory findings of cytokine storm, including high serum IL-6 levels, and generally required inotropic support to increase cardiac output with rare need for extracorporeal membrane oxygenation. Almost all of these children no longer required intensive care after only a few days and completely recovered, although rare deaths resulted from complications of extracorporeal membrane oxygenation. Case series of children presenting with this condition have now been reported from the UK, Italy, Spain, France and Switzerland, and the United States. The Centers for Disease Control and Prevention (CDC) has developed a case definition for use in the United States and has termed the condition multisystem inflammatory syndrome in children (MIS-C). If MIS-C is indeed related to infection with SARS-CoV-2, the pathophysiological mechanism of disease is unclear.

Very few studies have addressed the immune responses to SARS-CoV2 (either humoral or cell mediated immunity) in children. It is therefore necessary to study the immune responses in asymptomatic infections, prior infections and MIS-C to understand the pathogenesis of the disease.

Whole-genome sequencing of pathogens, especially viruses, is a powerful tool to generate rapid information on outbreaks, resulting in effective understanding of the introduction of the infection, dynamics of transmission, and impact of informed outbreak control decisions. In- deed, genomic data can be used to identify pathogen genes interacting with the host and allows characterisation of the more evolutionary constrained regions of a pathogen genome, which should be preferentially targeted to avoid rapid drug and vaccine escape mutants. (1). As the SARS-CoV-2 virus races around the world across the different population, there needs to be a consolidated effort to understand the divergence of demographically distributed strains. Since the transmission of SARS-CoV-2 is subject to the extent of human interaction, the insights from the correlation of genetic diversity would give vital information to tackle this transmission.

Recent published studies have reported that when comparing the 305 Indian SARS-CoV-2 genomes, a number of nucleotide variants or segregating sites being identified. Recent literature report that there is the presence of multiple lineages of SARS-CoV-2 in India in different geographic regions. 20A and 20B together (belonging to the former haplotype of A2a) are the predominant haplotypes at pan India level and in each region. Interestingly, the haplotypes were differentially distributed in different regions. While the 20A were most abundant in Northern and Eastern India, 20B was found to be the most abundant haplotype in Western and Southern India. The ancestral haplotypes of 19A and 19B were mostly found in Northern and Eastern India, with 19B being the most abundant in the latter region. While multiple haplotypes were introduced during the early part of the outbreak in March-May 2020, the 20A, B and C haplotypes (A2a) became the predominant haplotypes in all regions by June 2020. However, there are no studies that have characterised the viral diversity in this pediatric population and its association with immunological response and disease severity, in SARS-CoV-2 infected children.

Study objectives:

  • To perform systems immunology of SARS-CoV2 infection, COVID-19 disease and MIS-C in children
  • To identify the SARS-CoV2 viral diversity in the pediatric population and correlate with immune responses and disease severity.
03

Conditions studied

  • SARS-CoV2 Infection
  • Multisystem Inflammatory Syndrome in Children
04

Who can participate

Ages eligible
1 Year to 15 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Children attending outpatient clinics and admitted in the wards of Institute Of Child Health and Hospital for Children, Rainbow Childrens Hospital and Dr. Mehta's Childrens Hospitals, Chennai.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children between 1 to 15 years of age
  • Willing to provide (parents)/assent
  • For Group 1 - Positive or Negative for COVID-19 by RT-PCR but positive for SARS-CoV2 IgG
  • For Group 2 - Positive for COVID-19 by RT-PCR but negative for SARS-CoV2 IgG
  • For Group 3 - Positive for COVID-19 by RT-PCR or positive for SARS-CoV2 IgG antibody
  • For Group 4 - Control children who are negative for both RT-PCR and IgG antibody

Exclusion criteria

Exclusion Criteria:

  • Severely or anemic (WHO criteria in children) or malnourished
  • History of any illness or condition which, in the investigator's judgment, may substantially increase the risk associated with the participant's participation in the protocol, or compromise the scientific objectives
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
180 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Group 1

    Prior SARS-CoV2 infection as defined by being positive for IgG

  • Group 2

    COVID-19 disease as defined as children positive by RT-PCR

  • Group 3

    Children with MIS-C according to the WHO or CDC criteria

  • Group 4

    Control children who are negative for both RT-PCR and antibody

06

What researchers measure

Primary outcomes

  1. Characterization of immune responses

    Immune responses in children with SARS-CoV2 infection and multisystem inflammatory syndrome in children (MIS-C) infection and its association of SARS-CoV2 viral diversity

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Rajamanickam A, Nathella PK, Venkataraman A, Varadarjan P, Kannan S, Pandiarajan AN, Renji RM, Elavarasan E, Thimmaiah A, Sasidaran K, Krishnamoorthy N, Natarajan S, Ramaswamy G, Sundaram B, Putlibai S, Hissar S, Selladurai E, Uma Devi KR, Nutman TB, Babu S. Unique cellular immune signatures of multisystem inflammatory syndrome in children. PLoS Pathog. 2022 Nov 2;18(11):e1010915. doi: 10.1371/journal.ppat.1010915. eCollection 2022 Nov. PubMed 36322537 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2020 (actual). Primary completion is estimated for Dec 2024, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2021
First posted
Apr 14, 2021
StartActual
Dec 23, 2020
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2024
Last update
May 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04844242
Lead sponsor
Tuberculosis Research Centre, India
Responsible party
Sponsor
First posted
Apr 14, 2021
Start date
Dec 23, 2020
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
May 30, 2024

Study contacts

PAVAN KUMAR, PhD
Contact
pavankumarn@nirt.res.in
9940292543

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion